Blinatumomab (MT103) is a lymphoma-directed, recombinant bispecific single-chain antibody that was generated using Micromet's proprietary BiTEŽ antibody technology. Blinatumomab consists of four immunoglobulin variable domains assembled into a single polypeptide chain. Two of the variable domains form the binding site for CD19, a cell surface antigen expressed on most B cells and B tumor cells. The other two variable domains form the binding site for the CD3 complex on T cells. The resulting recombinant molecule is produced by fermentation with eukaryotic cells. BiTE antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. Interim data from the ongoing phase 1 study in advanced NHL patients have shown clinical proof of concept with clinical activity including confirmed partical and complete responses after Blinatumomab monotherapy.
Format
BiTEantibody
Target
CD19 (surface antigen specific for B cells)
Status
Ongoing phase 2 clinical trial in acute lymphoblastic leukemia (ALL)
Ongoing phase 1 clinical trial in non-Hodgkin's lymphoma (NHL)
Orphan drug designation for chronic lymphocytic leukemia (CLL)
Orphan drug designation for mantle cell lymphoma
Clinical Results
ASH presentation and posters Publication in Science Magazine
